edoc

Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis

Imfeld, Patrick and Bodmer, Michael and Jick, Susan S. and Meier, Christoph R.. (2015) Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. Drug safety, 38 (10). pp. 909-919.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/41941/

Downloads: Statistics Overview

Abstract

Previous observational studies have associated benzodiazepine use with an increased risk of dementia. However, limitations in the study methods leave questions unanswered regarding the interpretation of the findings.; A case-control analysis was conducted using data from the UK-based Clinical Practice Research Datalink (CPRD). A total of 26,459 patients aged ≥65 years with newly diagnosed Alzheimer's disease (AD) or vascular dementia (VaD) between 1998 and 2013 were identified and matched 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. Adjusted odds ratios (aORs) were calculated with 95% confidence intervals (CIs) of developing AD or VaD in relation to previous benzodiazepine use, stratified by duration and benzodiazepine type.; The aOR (95% CI) of developing AD for those who started benzodiazepines <1 year before diagnosis was 2.20 (1.91-2.53), and fell to the null for those who started between 2 and <3 years before [aOR 0.99 (0.84-1.17)]. The aOR (95% CI) of developing VaD for those who started benzodiazepines <1 year before diagnosis was 3.30 (2.78-3.92), and fell close to the null for those who started between 3 and <4 years before [aOR 1.16 (0.96-1.40)]. After accounting for benzodiazepine use initiated during this prodromal phase, long-term use of benzodiazepines was not associated with an increased risk of developing AD [aOR 0.69 (0.57-0.85)] or VaD [aOR 1.11 (0.85-1.45)].; After taking a prodromal phase into consideration, benzodiazepine use was not associated with an increased risk of developing AD or VaD.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Klinische Pharmazie/Spitalpharmazie (Meier)
UniBasel Contributors:Meier, Christoph R. and Imfeld, Patrick and Bodmer, Michael
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Adis International
ISSN:0114-5916
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:20 Sep 2016 09:25
Deposited On:20 Sep 2016 09:25

Repository Staff Only: item control page